Tranquillo programme describes how phase 3 ritlecitinib trials will be assessed
Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo
What the study says
This publication describes the design of the Tranquillo phase 3 programme investigating oral ritlecitinib for nonsegmental vitiligo. The programme includes placebo-controlled studies, an extension study and planned analyses of repigmentation, safety and response durability. Facial and total Vitiligo Area Scoring Index measures are among the planned outcomes. For readers following drug development, the paper explains what evidence the trials are designed to collect. It reports study protocols, not completed phase 3 efficacy results, and does not establish approval or suitability for an individual patient.
How to interpret this finding
Protocol paper: planned endpoints are not demonstrated treatment outcomes.
Research findings describe groups of participants. Discuss their relevance to your own care with your clinician.
References & original sources
These links identify the actual paper, its indexed record and available full text.
- 01PubMed indexed recordhttps://pubmed.ncbi.nlm.nih.gov/42171987/
- 02Original publicationhttps://doi.org/10.1007/s13555-026-01724-y
- 03Full text in PubMed Centralhttps://pmc.ncbi.nlm.nih.gov/articles/PMC13280265/
- 04Tranquillo trial registrationhttps://clinicaltrials.gov/study/NCT05583526
- 05Tranquillo extension registrationhttps://clinicaltrials.gov/study/NCT06163326
- 06Tranquillo 2 registrationhttps://clinicaltrials.gov/study/NCT06072183
Image source & reuse
Don Bliss (Illustrator) / National Cancer Institute
Context illustration: skin layers and melanocytes, from the National Cancer Institute. Not an image from the study.
View original image sourcePublic domain
